Patent RU-2261245-C2 (RU)
Inventor: EHRIKSSON TOMAS
IPC: A61P29/00
Filed: 2001-06-14
Granted: 2005-09-27
Abstract: FIELD: organic chemistry, medicine, pharmacy. 
     SUBSTANCE: invention relates to new compounds of the formula (I):   wherein m = 0, 1, 2 or 3; each R 1  represents independently halogen atom, cyano-group, hydroxyl, (C 3 -C 6 )-cycloalkyl, (C 1 -C 6 )-alkoxy-group, (C 1 -C 6 )-halogenalkyl, (C 1 -C 6 )-halogenalkoxy-group, -NR 9 R 10 , (C 3 -C 6 )-cycloalkylamino-, (C 1 -C 6 )-alkylthio-, (C 1 -C 6 )-alkylcarbonylamino-group or (C 1 -C 6 )-alkyl; X represents -O- or CH 2 -, OCH 2 -, CH 2 O-, CH 2 NH-, NH-; Y represents nitrogen atom (N) or group CH under condition that when X represents -O- or CH 2 O-, CH 2 NH- or NH-group then Y represents group CH; Z 1  represents a bond or group (CH 2 ) q  wherein q = 1 or 2; Z 2  represents a bond or group CH 2  under condition that both Z 1  and Z 2  can't represent a bond simultaneously; Q represents -O- or sulfur atom (S) or group CH 2  or NH; R 2  represents group of the formula:   n = 0; each R 4 , R 5 , R 6  and R 7  represents independently hydrogen atom (H), (C 1 -C 6 )-alkyl either R 4 , R 5 , R 6  and R 7  represent in common (C 1 -C 4 )-alkylene chain joining two carbon atoms to which they are bound to form 4-7-membered saturated carbon ring, either each R 5 , R 6  and R 7  represents hydrogen atom, and R 4  and R 8  in common with carbon atoms to which they are bound form 5-6-membered saturated carbon ring; R 8  represents hydrogen atom (H), (C 1 -C 6 )-alkyl or it is bound with R 4  as determined above; each R 9  and R 10  represents independently hydrogen atom (H), (C 1 -C 6 )-alkyl; R 15  represents (C 2 -C 6 )-alkyl, (C 2 -C 6 )-alkenyl, (C 3 -C 6 )-cycloalkyl, (C 5 -C 6 )-cycloalkenyl, adamantyl, phenyl or saturated or unsaturated 5-10-membered heterocyclic ring system comprising at least one heteroatom taken among nitrogen, oxygen and sulfur atoms wherein each group can be substituted with one or more substitute taken independently among nitro-group, hydroxyl, oxo-group, halogen atom, carboxyl, (C 1 -C 6 )-alkyl, (C 1 -C 6 )-alkoxy-, (C 1 -C 6 )-alkylthio-group, (C 1 -C 6 )-alkylcarbonyl, (C 1 -C 6 )-alkoxycarbonyl, phenyl and -NHC(O)-R 17  under condition that R 15  doesn't represent unsubstituted 1-pyrrolidinyl, unsubstituted 1-piperidinyl or unsubstituted 1-hexamethyleneiminyl group; t = 0, 1, 2 or 3; each R 16  represents independently halogen atom, cyano-group, hydroxyl, (C 3 -C 6 )-cycloalkyl, (C 1 -C 6 )-alkoxy-group, (C 1 -C 6 )-halogenalkyl, (C 1 -C)-halogenalkoxy-group, -NR 18 R 19 , (C 1 -C 6 )-cycloalkylamino-, (C 1 -C 6 )-alkylthio-, (C 1 -C 6 )-alkylcarbonylamino-group, (C 1 -C 6 )-alkyl; R 17  means (C 1 -C 6 )-alkykl, amino-group, phenyl; each R 18  and R 19  means independently hydrogen atom (H), (C 1 -C 6 )-alkyl, or its pharmaceutically acceptable salt or solvate. Compounds of the formula (I) elicit activity of a modulating agent with respect to activity of chemokine MIP-1α receptors that allows their using in pharmaceutical composition in treatment of inflammatory diseases. 
     EFFECT: valuable medicinal properties of new compounds. 
     14 cl, 98 ex